A history of the role of the hERG channel in cardiac risk assessment

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 1, 2013, Pages 13-22

  Rampe, David ^a   Brown, Arthur M ^b  

^a SANOFI   (France)

^b ChanTest Corporation   (United States)

Author keywords

Agonists; Blockers; HERG; Methods; Modeling; Patch clamp; Trafficking

Indexed keywords

4 [3 (6 METHOXY 4 QUINOLINYL) 3 OXOPROPYL] 1 [3 (2,3,5 TRIFLUOROPHENYL) 2 PROPYNYL] 3 PIPERIDINECARBOXYLIC ACID; A 935142; ASTEMIZOLE; CISAPRIDE; COCAINE; DEXTROPROPOXYPHENE; ERYTHROMYCIN; GREPAFLOXACIN; HALOPERIDOL; ICA 105574; LEVACETYLMETHADOL; METHADONE; MIBEFRADIL; NS 1643; PD 118057; PD 307243; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL STIMULATING AGENT; SERTINDOLE; TERFENADINE; THIORIDAZINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; BINDING AFFINITY; CARDIOVASCULAR RISK; COMPUTER MODEL; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DISEASE MARKER; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG INTERACTION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; ERROR; ETHER A GO GO RELATED GENE; GENE EXPRESSION; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; IC 50; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PATCH CLAMP; PROTEIN FUNCTION; PROTEIN TRANSPORT; QT PROLONGATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TORSADE DES POINTES;

AGONISTS; BLOCKERS; HERG; HUMAN ETHER-A-GO-GO-RELATED GENE; METHODS; MODELING; PATCH CLAMP; TDP; THOROUGH QT TRIAL; TORSADES DE POINTES; TQT; TRAFFICKING;

ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; PATCH-CLAMP TECHNIQUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TORSADES DE POINTES;

EID: 84880035894     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.03.005     Document Type: Article

References (118)

1. Anson B.D., Weaver J.G., Ackerman M.J., Akinsete O., Henry K., January C.T., et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005, 365:682-686.
2. Barhanin J., Lesage F., Guillemare E., Fink M., Lazdunski M., Romey G. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 1996, 384:78-80.
3. Bischoff U., Schmidt C., Netzer R., Pongs O. Effects of fluoroquinolones on HERG currents. European Journal of Pharmacology 2000, 406:341-343.
4. Bran S., Murray W.A., Hirsch I.B., Palmer J.P. Long QT syndrome during high-dose cisapride. Archives of Internal Medicine 1995, 155:765-768.
5. + and modulated by cAMP. Nature 1993, 365:445-448.
6. Calderone V., Testai L., Martinotti E., Del Tacca M., Breschi M.C. Drug-induced block of cardiac HERG potassium channels and development of torsades de pointes arrhythmias: The case of antipsychotics. Journal of Pharmacy and Pharmacology 2005, 57:151-161.
7. +) channel blockers. Journal of Medicinal Chemistry 2002, 45:3844-3853.
8. Clark A., Love H. Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions. International Journal of Cardiology 1991, 33:165-167.
9. Coraboeuf E., Nargeot J. Electrophysiology of human cardiac cells. Cardiovascular Research 1993, 27:1713-1725.
10. Cordes J.S., Sun Z., Lloyd D.B., Bradley J.A., Opsahl A.C., Tengowski M.W., et al. Pentamidine reduces hERG expression to prolong the QT interval. British Journal of Pharmacology 2005, 145:15-23.
11. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
12. Davies A.J., Harindra V., McEwan A., Ghose R.R. Cardiotoxic effect with convulsions in terfenadine overdose. British Medical Journal 1989, 298:325.
13. De Bruin M.L., Pettersson M., Meyboom R.H.B., Hoes A.W., Leufkens H.G.M. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. European Heart Journal 2005, 26:590-597.
14. Dennis A.T., Nassal D., Deschenes I., Thomas D., Ficker E. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG. Journal of Biological Chemistry 2011, 286:34413-34425.
15. Dennis A.T., Wang L., Wan H., Nassal D., Deschenes I., Ficker E. Molecular determinants of pentamidine-induced hERG trafficking inhibition. Molecular Pharmacology 2012, 81:198-209.
16. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circulation Research 1996, 79:659-668.
17. + conduction and selectivity. Science 1998, 280:69-77.
18. Drolet B., Zhang S., Deschenes D., Rail J., Nadeau S., Zhou Z., et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. Journal of Cardiovascular Electrophysiology 1999, 10:1597-1604.
19. Dumotier B.M., Deurinck M., Yang Y., Traebert M., Suter W. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: A database review and analysis. Pharmacology and Therapeutics 2008, 119:152-159.
20. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. Journal of Pharmacology and Experimental Therapeutics 2002, 301:427-434.
21. Farid R., Day T., Friesner R.A., Pearlstein R.A. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorganic & Medicinal Chemistry 2006, 14:3160-3173.
22. Ferreira S., Crumb W.J., Carlton C.G., Clarkson C.W. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. Journal of Pharmacology and Experimental Therapeutics 2001, 299:220-226.
23. Ficker E., Dennis A.T., Wang L., Brown A.M. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG. Circulation Research 2003, 92:e87-e100.
24. Ficker E., Kuryshev Y.A., Dennis A.T., Obejero-Paz C., Wang L., Hawryluk P., et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular Pharmacology 2004, 66:33-44.
25. Follmer C.H., Colatsky T.J. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990, 82:289-293.
26. Fozzard H.A., Hanck D.A. Structure and function of voltage-dependent sodium channels: Comparison of brain II and cardiac isoforms. Physiological Reviews 1996, 76:887-926.
27. Gerlach A.C., Stoehr S.J., Castle N.A. Pharmacological removal of human ether-a-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Molecular Pharmacology 2010, 77:58-68.
28. Gibbons S. 'Legal highs'-novel and emerging psychoactive drugs: A chemical overview for the toxicologist. Clinical Toxicology (Phildelphia, Pa) 2012, 50:15-24.
29. Ginman T., Viklund J., Malmstrom J., Blid J., Emond R., Forsblom R., et al. Core refinement towards permeable b-secretase (BACE-1) inhibitors with low hERG activity. Journal of Medicinal Chemistry 2012, 10.1021/jm3011349.
30. Gordon E., Lozinskaya I.M., Lin Z., Semus S.F., Blaney F.E., Willette R.N., et al. 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Molecular Pharmacology 2008, 73:639-651.
31. Guo J., Massaeli H., Li W., Xu J., Luo T., Shaw J., et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics 2007, 321:911-920.
32. Guo J., Zhan S., Lees-Miller J.P., Teng G., Duff H.J. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm 2005, 2:860-866.
33. +) channel by direct block and disruption of protein trafficking. European Journal of Pharmacology 2011, 650:138-144.
34. Hansen R.S., Diness T.G., Christ T., Demnitz J., Ravens U., Olesen S.P., et al. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Molecular Pharmacology 2006, 69:266-277.
35. Iannini P.B. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opinion on Drug Safety 2002, 1:121-128.
36. Jamieson C., Moir E.M., Rankovic Z., Wishart G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. Journal of Medicinal Chemistry 2006, 49:5029-5046.
37. Jiang Y., Lee A., Chen J., Cadene M., Chait B.T., MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002, 417:515-522.
38. +) channel by the antidepressant drug amitriptyline. British Journal of Pharmacology 2000, 129:1474-1480.
39. + channel. Molecular Pharmacology 2005, 67:827-836.
40. Kang J., Chen X.L., Wang H., Ji J., Reynolds W., Lim S., et al. Cardiac ion channel effects of tolterodine. Journal of Pharmacology and Experimental Therapeutics 2004, 308:935-940.
41. +) channel by the neuroleptic pimozide. European Journal of Pharmacology 2000, 392:137-140.
42. + channel HERG. Molecular Pharmacology 2001, 59:122-126.
43. Kaplan W.D., Trout W.E. The behavior of four neurological mutants of Drosophila. Genetics 1969, 61:399-409.
44. +) currents. Journal of Pharmacology and Experimental Therapeutics 2002, 303:688-694.
45. Kireeva N., Kuznetsov S.L., Bykov A.A., Tsivadze A. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: Discriminative vs. generative classification models. SAR and QSAR in Environmental Research 2013, 24:103-117.
46. Kirsch G.E., Trepakova E.S., Brimecombe J.C., Sidach S.S., Erickson H.D., Kochan M.C., et al. Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern. Journal of Pharmacological and Toxicological Methods 2004, 50:93-101.
47. Klon A.E. Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development. Expert Opinion on Drug Metabolism & Toxicology 2010, 6:821-833.
48. Kongsamut S., Kang J., Chen X.-L., Roehr J., Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European Journal of Pharmacology 2002, 450:37-41.
49. Kunze D.L., Lacerda A.E., Wilson D.L., Brown A.M. Cardiac Na currents and the inactivating, reopening, and waiting properties of single cardiac Na channels. Journal of General Physiology 1985, 86:691-719.
50. Kuryshev Y.A., Bruening-Wright A., Brown A.M., Kirsch G.E. Increased cardiac risk in concomitant methadone and diazepam treatment: Pharmacodynamics interactions in cardiac ion channels. Journal of Cardiovascular Pharmacology 2010, 56:420-430.
51. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. Journal of Pharmacology and Experimental Therapeutics 2005, 312:316-323.
52. Lacerda A.E., Kuryshev Y.A., Chen Y., Renganathan M., Eng H., Danthi S.J., et al. Alfuzosin delays cardiac repolarization by a novel mechanism. Journal of Pharmacology and Experimental Therapeutics 2008, 324:427-433.
53. Lewin M.B., Bryant R.M., Fenrich A.L., Grifka R.G. Cisapride-induced long QT interval. Journal of Pediatrics 1996, 128:279-281.
54. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. European Addiction Research 2005, 11:44-49.
55. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology 2004, 43:369-379.
56. Mbai M., Rajamani S., January C.T. The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels. Cardiovascular Research 2002, 55:799-805.
57. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:12329-12333.
58. + channel by the gastrointestinal prokinetic agent cisapride. American Journal of Physiology 1997, 273:H2534-H2538.
59. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantilena L.R. Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association 1990, 264:2788-2790.
60. Morgan T.K., Sullivan M.E. An overview of class III electrophysiological agents: A new generation of antiarrhythmic therapy. Progress in medicinal chemistry 1992, 29:65-108. Elsevier Science Publishers B. V., Amsterdam. G.P. Ellis, D.K. Luscombe (Eds.).
61. O'Leary M.E. Inhibition of human ether-a-go-go potassium channels by cocaine. Molecular Pharmacology 2001, 59:269-277.
62. O'Leary M.E. Inhibition of HERG potassium channels by cocaethylene: A metabolite of cocaine and ethanol. Cardiovascular Research 2002, 53:59-67.
63. Pearlstein R.A., Vaz R.J., Kang J., Chen X.-L., Preobrazhenskaya M., Shchekotikhin A.E., et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorganic & Medicinal Chemistry Letters 2003, 13:1829-1835.
64. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 2008, 154:1382-1399.
65. Raffa R.B., Burmeister J.J., Yuvasheva E., Pergolizzi J.V. QTc interval prolongation by d-propoxyphene: What about other analgesics?. Expert Opinion on Pharmacotherapy 2012, 13:1397-1409.
66. + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. British Journal of Pharmacology 2006, 149:481-489.
67. Rampe D., Murawsky M.K., Grau J., Lewis E.W. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. Journal of Pharmacology and Experimental Therapeutics 1998, 286:788-793.
68. Rampe D., Roy M.L., Dennis A., Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Letters 1997, 417:28-32.
69. Recanatini M., Cavalli A., Masetti M. Modeling hERG and its interactions with drugs: Recent advances in light of current potassium channel simulations. Chemistry and Medicinal Chemistry 2008, 3:523-535.
70. Rees S.A., Curtis M.J. Selective IK block as an antiarrhythmic mechanism in ischemic heart disease: Effect of UK 66,914 in rat and rabbit. British Journal of Pharmacology 1993, 108:139-145.
71. Roden D.M., Woosley R.L. QT prolongation and arrhythmia suppression. American Heart Journal 1985, 109:411-415.
72. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. European Journal of Medical Chemistry 1999, 42:260-266.
73. Roy M., Dumaine R., Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996, 94:817-823.
74. Salata J.J., Jurkiewicz N.K., Wallace A.A., Stupienski R.F., Guinosso P.J., Lynch J.J. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circulation Research 1995, 76:110-119.
75. Sanguinetti M.C. HERG1 channelopathies. Pflugers Archiv: European Journal of Physiology 2010, 460:265-276.
76. Sanguinetti M.C., Curran M.E., Zou A., Shen J., Spector P.S., Atkinson D.L., et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996, 384:80-83.
77. Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanistic link between and inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81:299-307.
78. + current. Differential sensitivity to block by class III antiarrhythmic agents. Journal of General Physiology 1990, 96:195-215.
79. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends in Pharmacological Sciences 2005, 26:119-124.
80. Seebohm G. Activators of cation channels: Potential in treatment of channelopathies. Molecular Pharmacology 2005, 67:585-588.
81. Selzer A., Wray H.W. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964, 30:17-26.
82. Shah R.R. Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives. British Journal of Pharmacology 2010, 159:58-69.
83. Smith P.L., Baukrowitz T., Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996, 379:833-836.
84. Snyders D.J., Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Molecular Pharmacology 1996, 49:949-955.
85. + channel. Open channel block by methanesulfonanilides. Circulation Research 1996, 78:499-503.
86. Stanat S.J., Carlton C.G., Crumb W.J., Agrawal K.C., Clarkson C.W. Characterization of the inhibitory effects of erythromycin and clarithromycin on the hERG potassium channel. Molecular and Cellular Biochemistry 2003, 254:1-7.
87. Stansfeld P.J., Gedeck P., Gosling M., Cox B., Mitcheson J.S., Sutcliffe M.J. Drug block of the hERG potassium channel: Insights from modeling. Proteins 2007, 68:568-580.
88. Striessnig J. Pharmacology, structure and function of cardiac L-type calcium channels. Cellular Physiology and Biochemistry 1999, 9:242-269.
89. Su Z., Limberis J., Souers A., Kym P., Mikhail A., Houseman K., et al. Electrophysiologic characterization of a novel hERG channel activator. Biochemical Pharmacology 2009, 77:1383-1390.
90. Subasinghe N.L., Lanter J., Markotan T., Opas E., Mckenney S., Crysler C., et al. A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters 2013, 23:1063-1069.
91. Suessbrich H., Schonherr R., Heinemann S.H., Attali B., Land F., Busch A.E. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. British Journal of Pharmacology 1997, 120:968-974.
92. Suessbrich H., Waldegger S., Lang F., Busch A.E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Letters 1996, 385:77-80.
93. Sun H., Liu X., Xiong Q., Shikano S., Li M. Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. Journal of Biological Chemistry 2006, 281:5877-5884.
94. Takemasa H., Nagatomo T., Abe H., Kawakami K., Igarashi T., Tsurugi T., et al. British Journal of Pharmacology 2008, 153:439-447.
95. Teschemacher A.G., Seward E.P., Hancox J.C., Witchel H.J. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. British Journal of Pharmacology 1999, 128:479-485.
96. Tie H., Walker B.D., Singleton C.B., Valenzuela S.M., Bursill J.A., Wyse K.R., et al. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. British Journal of Pharmacology 2000, 130:1967-1975.
97. Tseng G.N., Sonawane K.D., Korolkova Y.V., Zhang M., Liu J., Grishin E.V., et al. Probing the outermouth structure of the HERG channel with peptide toxin footprinting and molecular modeling. Biophysical Journal 2007, 92:3524-3540.
98. Ulens C., Daenens P., Tytgat J. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovascular Research 1999, 44:568-578.
99. +) channels: Structure, function, and physiological significance. Physiological Reviews 2012, 92:1393-1478.
100. Vaughan Williams E.M., Millar J.S., Campbell T.J. Electrophysiological effects of labetalol on rabbit atrial, ventricular and Purkinje cells, in normoxia and hypoxia. Cardiovascular Research 1982, 16:233-239.
101. Veldkamp M.W., van Ginneken A.C., Opthof T., Bouman L.N. Delayed rectifier channels in human ventricular myocytes. Circulation 1995, 92:3497-3504.
102. Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. Blockage of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. Journal of Pharmacology and Experimental Therapeutics 2002, 302:320-327.
103. Walker B.D., Singleton C.B., Bursill J.A., Wyse K.R., Valenzuela S.M., Qui M.R., et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states. British Journal of Pharmacology 1999, 128:444-450.
104. Wallis R.M. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. British Journal of Pharmacology 2010, 159:115-121.
105. Wang Z., Fermini B., Nattel S. Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovascular Research 1994, 28:1540-1546.
106. Wang L., Wible B.A., Wan X., Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. Journal of Pharmacology and Experimental Therapeutics 2007, 320:525-534.
107. Warmke J., Drysdale R., Ganetzky B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 1991, 252:1560-1562.
108. Warmke J.W., Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:3438-3442.
109. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., Brown A.M. HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. Journal of Pharmacological and Toxicological Methods 2005, 52:136-145.
110. + channels localized to a single negatively charged residue. Nature 1995, 371:246-249.
111. Wiley J.F., Gelber M.L., Henretig F.M., Wiley C.C., Sandhu S., Loiselle J. Cardiotoxic effects of astemizole overdose in children. Journal of Pediatrics 1992, 120:799-802.
112. Witchel H.J., Hancox J.C., Nutt D.J. Psychotropic drugs, cardiac arrhythmia, and sudden death. Journal of Clinical Psychopharmacology 2003, 23:58-77.
113. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. Journal of the American Medical Association 1993, 269:1532-1536.
114. Wu Z.Y., Yu D.J., Soong T.W., Dawe G.S., Bian J.S. Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis. Journal of Biological Chemistry 2011, 286:22186-22194.
115. + minK, potassium channels. Molecular Pharmacology 2001, 59:1069-1076.
116. Zhang S., Zhou Z., Gong Q., Makielski J.C., January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circulation Research 1999, 84:989-998.
117. Zhou J., Augelli-Szafran C.E., Bradley J.A., Chen X., Koci B.J., Volberg W.A., et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Molecular Pharmacology 2005, 68:876-884.
118. Zhou Z., Gong Q., January C.T. Correction of defective protein trafficking of a mutant hERG potassium channel in human long QT syndrome. The Journal of Biological Chemistry 1999, 274:31123-31126.